High throughput identification of human monoclonal antibodies and heavy-chain-only antibodies to treat snakebite.

ABSTRACT: Snakebite envenoming is a priority Neglected Tropical Disease that causes an estimated 81,000-135,000 fatalities each year. The development of a new generation of safer, affordable, and accessible antivenom therapies is urgently needed. With this goal in mind, rigorous characterisation of the specific toxins in snake venom is key to generating novel therapies for snakebite. Monoclonal antibodies directed against venom toxins are emerging as potentially strong candidates in the development of new snakebite diagnostics and treatment. Venoms comprise many different toxins of which several are responsible for their pathological effects. Due to the large variability of venoms within and between species, formulations of combinations of human antibodies are proposed as the next generation antiven

SUBMITTER: Slagboom J 

PROVIDER: S-EPMC10901844 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature